Navigation Links
TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
Date:1/31/2008

SAN DIEGO, Jan. 31 /PRNewswire/ -- TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)

The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce V617F-expressing cell populations in a dose-dependant manner without adversely impacting normal hematopoeisis. The reduction of V617F-expressing cell populations correlated with improved survival and reduced morbidity. There are no currently approved specific therapies for PV, ET and PMF. These disorders are estimated to affect approximately 200,000 patients in the United States and more than twice that total worldwide.

The current clinical trial is being conducted at multiple centers in the USA. The trial is expected to enroll between 40-80 patients. Primary goals of this open label dose escalating protocol include identification of a maximum tolerated dose (MTD), accumulation of safety data, measurement of drug effect on surrogate markers, biomarkers, and presumptive clinical endpoints.

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases.

TargeGen initiated operations in 2002 and has raised capital
'/>"/>

SOURCE TargeGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Researchers from University Hospitals Case Medical Center Seidman Cancer ... will present data from several new studies, including a ... patients with advanced solid tumors and a first-of-its-kind analysis ... at the 51 st American Society for Clinical ... . Jennifer Eads , MD, ...
(Date:6/1/2015)... -  Ergoresearch Ltd (TSXV: ERG) – based in ... orthèses et biomécanique» banner  – announces its results for ... amounts in the present release are in Canadian currency. ... 2015 ended this past March 31, 2015 totaled $ 3,299,994 decreasing by ... quarter ended March 31, 2014. This decrease can be explained ...
(Date:6/1/2015)... Women who took vitamin D and calcium supplements had the ... take the supplements, according to a study published today in ... European Menopause and Andropause Society. The study, ... Women,s Health Initiative , one of the largest clinical ... death, disability and impaired quality of life in menopausal women. ...
Breaking Medicine Technology:UH Case Medical Center Experts to Present Data at 51st ASCO Annual Meeting 2UH Case Medical Center Experts to Present Data at 51st ASCO Annual Meeting 3Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 3Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 4Vitamin D and Calcium Supplements Do Not Improve Menopausal Symptoms 2Vitamin D and Calcium Supplements Do Not Improve Menopausal Symptoms 3Vitamin D and Calcium Supplements Do Not Improve Menopausal Symptoms 4
... connectivity enabled by Unlimited Systems Interlink integration platform, Navigating ... cancer clinics easily meet many of the HITECH Act ... and money by reducing duplicate data entry, streamlining patient ... and reduced denials. Clinics can provide patients ...
... N.J., Oct. 18, 2011 Johnson & Johnson (NYSE: ... the third quarter of 2011, an increase of 6.8% as ... 2.6% and the positive impact of currency was 4.2%.  Domestic ... of 8.3% and a positive currency impact of 8.1%. ...
Cached Medicine Technology:Navigating Cancer and Unlimited Systems Partner to Provide Cancer Clinics With IT Interoperability to Attain HITECH Act Incentives 2Johnson & Johnson Reports 2011 Third-Quarter Results 2Johnson & Johnson Reports 2011 Third-Quarter Results 3Johnson & Johnson Reports 2011 Third-Quarter Results 4Johnson & Johnson Reports 2011 Third-Quarter Results 5Johnson & Johnson Reports 2011 Third-Quarter Results 6Johnson & Johnson Reports 2011 Third-Quarter Results 7Johnson & Johnson Reports 2011 Third-Quarter Results 8Johnson & Johnson Reports 2011 Third-Quarter Results 9Johnson & Johnson Reports 2011 Third-Quarter Results 10Johnson & Johnson Reports 2011 Third-Quarter Results 11Johnson & Johnson Reports 2011 Third-Quarter Results 12Johnson & Johnson Reports 2011 Third-Quarter Results 13Johnson & Johnson Reports 2011 Third-Quarter Results 14
(Date:6/1/2015)... June 01, 2015 "This milestone opens ... were not previously able to buy and sell shares ... unsolicited orders and also make recommendations to clients as ... an ability to trade shares of our Company,” said ... and information requirements of OTCQB provides our investors greater ...
(Date:6/1/2015)... Note: Dr. Julian is available for interviews ... , A phase III trial funded by the National ... carcinoma in situ (DCIS) now have an additional tool ... (NSABP B-35/NRG Oncology) looked at more than 3,000 DCIS ... with tamoxifen to those who completed five years of ...
(Date:6/1/2015)... NY (PRWEB) June 01, 2015 For ... patients requesting celebrity features. Much like one would request ... stars’ noses, eyes, cheeks, chin and more to illustrate ... filtering apps like FaceTune are ushering in a new ... Manhattan facial plastic surgeon, Sam Rizk, MD, FACS notes ...
(Date:6/1/2015)... There’s never a good time to be sick and need ... , As of June 1, OSF HealthCare is offering ... the Internet. Patients throughout Illinois can access care whenever they ... busy. We know that getting in to see a provider ... it easier,” said Jeffry Tillery, MD, Chief Transformation Officer for ...
(Date:6/1/2015)... June 1, 2015 – Atlanta, GA – EB ... of hospital medicine, emergency medicine, and pediatric emergency medicine, ... its partnership with AgileMD to provide the content from ... mobile application format available on iPhones, iPads and ... excited about the June 1 launch of our hospital ...
Breaking Medicine News(10 mins):Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 3Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 4Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2Health News:OSF HealthCare Now Offering OSF OnCall 2Health News:OSF HealthCare Now Offering OSF OnCall 3Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3
... Serena Gordon HealthDay Reporter , WEDNESDAY, May ... the drug lenalidomide can significantly lengthen the time that ... disease, either after having a stem cell transplant or ... studies is whether or not the improved "progression-free" survival ...
... today released a wide-ranging compendium of resources ... and secure sharing of health information. ... Policies in Practice for Health Information Sharingor ... for electronic health information sharing, including informed ...
... Infectious diseasesboth old and newcontinue to exact a devastating ... the world. Vaccines remain the best line of ... Stephen Johnston, researchers at Arizona State University,s Biodesign Institute, ... Texas Southwestern Medical Center are using clever functional screening ...
... -- The rate at which Americans are hospitalized for stroke ... According to the U.S. National Center for Health Statistics (NCHS), ... people during the 1990s but had decreased again to under ... there were still about 800,000 hospitalizations for stroke in 1989 ...
... support and limited pressure to achieve the ,thin and beautiful, ... a new study looking at five factors that may help ... the context of a society where discontent with appearance is ... the University of Arizona in the US, and colleagues is ...
... HealthDay Reporter , TUESDAY, May 8 (HealthDay News) ... atrial fibrillation face a 14 percent greater risk of ... report. The raised risk remained higher even when ... stroke, the study authors noted. "Previously, there was ...
Cached Medicine News:Health News:New Drug Shows Promise for Myeloma Patients 2Health News:New Drug Shows Promise for Myeloma Patients 3Health News:Markle releases new resources for health information sharing implementation 2Health News:Markle releases new resources for health information sharing implementation 3Health News:Advanced genetic screening method may speed vaccine development 2Health News:Advanced genetic screening method may speed vaccine development 3Health News:Advanced genetic screening method may speed vaccine development 4Health News:Rate of Hospitalizations for Stroke Has Declined in U.S. 2Health News:Self-worth needs to go beyond appearance 2Health News:Irregular Heartbeat Poses Greater Stroke Risk for Women Than Men 2
Speculum with malleable plate to support flap during ablation of thestromal bed....
This adjustable lid speculum is angled 45 degrees and has 17 mm wire blades. It was designed to aspirate excess fluid around the eye during cataract and refractive procedures....
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Available with shaft straight or angled 45 degrees....
Open 13 mm blades. Screw-controlled locking mechanism. Dull finish....
Medicine Products: